

****Published February 2017****

MarketVIEW: Therapeutic cancer vaccines overview (CAT: VAMV072)

Product Name	:	MarketVIEW: Therapeutic cancer vaccines overview
Description	:	Overview of therapeutic cancer vaccines
Contents	:	Executive presentation (.pdf) + 1 Excel workbook (.xls)
Therapeutic Area	:	Cancer immunotherapy
Publication date	:	February 2017
Catalogue No	:	VAMV072

Background

Cancer is one of the leading causes of death worldwide causing approximately 1 in every 7 deaths. In 2012, 8.2 million people died of the disease with 14 million new cases recorded in that year (WHO Figures). In 2030, the number of new cancer cases is projected to be >22 million (50-70% increase) due to the increasing population age and size.

Cancer immunotherapy (active and passive) aims to harness the body's own immune system in the fight against tumour progression. In the past decade, this strategy has become the most promising in the search for novel cancer therapies. Recent breakthroughs include either tumour specific/bi-specific monoclonal antibodies (mAbs), checkpoint inhibitors, adoptive cell therapy and therapeutic cancer vaccines (peptides, dendritic cells, allogenic cells, autologous cells, oncolytic viruses). For the latter group, **Dendreon's Provenge® (Sipuleucel-T)** was the first therapeutic vaccine approved for any cancer.

This **MarketVIEW** product consists of a detailed Executive presentation (~100 slides) and MS-Excel work book summarizing current approaches in cancer immunotherapy with an in-depth focus on the therapeutic cancer vaccine category. Included is an analysis of over 300 verified cancer vaccine programs (Phase I-III) delineated by sponsor, sponsor type, mechanism, tumor type, results, and other relevant fields. Detailed case studies are presented for the identified late stage (Phase III) industry sponsored programs e.g. **PROSTVAC® Bavarian Nordic** with presentation of clinical trial data relevant to the Provenge® (Sipuleucel-T) reference for FDA approval. This analysis is recommended to any client wishing to understand quickly the commercial landscape of the therapeutic cancer vaccine field within the overview dynamic of cancer immunotherapy.

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to therapeutic cancer vaccines as approaches to cancer immunotherapy. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc.

PRODUCT CONTENTS:

Published February 2017 (CAT No: VAMV072)

****This product is composed of [one Excel workbook \(.xls\)](#)¹ and [an executive presentation \(.pdf\)](#)²

Contents
Executive summary
Cancer and immunotherapy
Cancer immunotherapy: broad approaches
Overview
Introduction to cancer vaccines
Types of cancer vaccines
Cancer vaccine approaches: cell-based vaccines
Cancer vaccine approaches: peptide-based vaccines
Cancer vaccine approaches: DNA vaccines
Cancer vaccine approaches: RNA vaccines
Cancer vaccine approaches: Viral vector vaccines
Cancer vaccine approaches: Oncolytic viruses
Approved therapeutic cancer vaccines
Provenge® (Sipuleucel-T)
Provenge® (Sipuleucel-T): Phase III data
Provenge® (Sipuleucel-T): Ongoing trials
Current R&D pipeline
Cancer vaccines: pipeline analysis methodology
Cancer vaccine trials (Phase I-III), by tumour type
Cancer vaccine trials, by phase and sponsor type 2016
Cancer vaccine trials, by tumour and sponsor type 2016
Cancer vaccine trial phases verified 2016 per tumour tissue
Cancer vaccine phase III trials per tumour type
Cancer vaccine trials conducted for single vs multiple tissue tumours - verified in 2016
Industry sponsored Phase II/III and Phase III cancer vaccine trials verified in 2016
Melanoma
Seviprostimut-L (POL-103A) - Polynoma
Seviprostimut-L (POL-103A): Phase II data
Prostate Cancer
PROSTVAC® (rilimogene galvacirepvac) - Bavarian Nordic
PROSTVAC® : Phase II data
PROSTVAC® : Phase III trial (ongoing)
PROSTVAC® : Key ongoing trials
ProstAtak® (AdV-tk) - Advantagene Inc
ProstAtak® (AdV-tk) - Phase II trial
DCVAC/PCa - Sotio

¹ Contents available on request

² Presentation titles may apply to more than one slide

Continued.....

DCVAC/PCa: Phase II data
DCVAC/PCa: Key ongoing trials
Brain Cancer
DCVax®-L - Northwest Biotherapeutics
DCVax®-L: Phase I/II DCVax-L Trials
DCVax®-L: Key ongoing trials
ICT-107 - Immunocellular Therapeutics Ltd
ICT-107: Phase II data
Ovarian Cancer
Vigil® (gemogenovatumel-T, FANGTM) - Gradalis
Vigil®: Phase II data
Vigil®: Key ongoing trials
Colon Cancer
ALLOSTIM® - Immunovative Therapies Ltd
ALLOSTIM®: Phase I/II data
ALLOSTIM®/ Allovax®: Key ongoing trials
Lung Cancer
Tedopi® (OSE2101) - OSE Immunotherapeutics
Tedopi® (OSE-2101, IDM-2101): Phase II data
Vaxira® (Racotumomab-alum, 1E10) - Recombio
Vaxira® (Racotumomab-alum, 1E10): Phase II data
EGF PTI (BV-NSCLC-002) - Bioven
EGF PTI (BV-NSCLC-002): Phase II data
HyperAcuteTM (Tergenpumatumel-L) - NewLink Genetics Corporation
HyperAcuteTM (Tergenpumatumel-L): Phase II study
Appendix: Historical analysis since 1991
Cancer vaccine trials to date: Historical view since 1991
Cancer vaccine trials to date - Result status historical view
Cancer Vaccine Trials to Date - Trial phase historical view
Cancer Vaccine Trials to Date - Trials conducted for single vs multiple tissue tumours - historical view
Cancer vaccine trials - Last verification dates
Cancer vaccine trials - Last verification dates 2001-2016 by tissue
Cancer vaccines: development history summary

Slide number = 99

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD **\$6995.00**/ GBP **£5780.00**[#] (Region license)*

[#] Indicative company rate only. Prevailing rate applied to date of transaction.

*A region is North America, Europe or ROW

For orders in the UK, VAT at 20.0% will be added to final invoice total

Agency/consultancy rates (commercial use) are available upon request

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com

This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



BIBLIOGRAPHY

1. Cancer immunoeediting: antigens, mechanisms, and implications to cancer immunotherapy. Vesely and Schreiber. *Ann N Y Acad Sci.* 2013 May;1284:1-5.
2. Adaptive immunity maintains occult cancer in an equilibrium state. Koebel et al. *Nature.* 2007 Dec 6;450(7171):903-7
3. Mechanism of Action of Immunotherapy. *Disis. Semin Oncol*41:S3-S13. 2014
4. Harnessing the immune system to improve cancer therapy. Papaioannou et al. *Ann Transl Med.* 2016 Jul;4(14):261
5. Available at: <https://www.Cancer and the Immune System, the Vital Connection>. Accessed December 2016.
6. Bispecific antibodies for cancer therapy. The light at the end of the tunnel? Chames and Baty. *MAbs.* 2009 Nov-Dec;1(6):539-47.
7. Bispecific antibodies. *Kontermann and Brinkmann. Drug Discovery Today* Volume 20, Number 7 July 2015
8. Adoptive T Cell Immunotherapy for Cancer. Perica et al. *Rambam Maimonides Med J.* 2015 Jan 29;6(1):e0004
9. Advances in Cancer Immunotherapy in Solid Tumors. Menon et al. *Cancers (Basel).* 2016 Nov 24;8(12)
10. Immune checkpoint inhibitors for cancer treatment. Park et al. *Arch Pharm Res.* 2016 Nov;39(11):1577-1587
11. Adapted from National Cancer Institute. Available at: <https://www.cancer.gov/about-cancer/causes-prevention/vaccines-fact-sheet#g4>. Accessed November 2016
12. A New Era in Anticancer Peptide Vaccines, Perez et al, *Cancer* 2010, **116**, 2071-2080
13. Peptide Based Vaccine Approaches for Cancer—A Novel Approach Using a WT-1 Synthetic Long Peptide and the IRX-2 Immunomodulatory Regimen, Naylor et al, *Cancers* 2011, 3, 3991-4009
14. MAGE-A3: an immunogenic target used in clinical practice, Esfandiary and Ghafouri-Fard, *Immunotherapy* (2015) 7(6), 683–704
15. Current developments in viral DNA vaccines: shall they solve the unsolved? Rajcani et al. *Rev Med Virol.* 2005; 15(5):303–325
16. Molecular mechanisms for enhanced DNA vaccine immunogenicity. Li and Petrovsky *Expert Rev Vaccines.* 2016;15(3):313-29
17. DNA vaccine for cancer immunotherapy. Yang et al. *Hum Vaccin Immunother.* 2014;10(11):3153-64
18. Therapeutic cancer vaccines: past, present, and future. Guo et al. *Advances in Cancer Research*, vol. 119, pp. 421–475, 2013.
19. RNA based vaccines. Ulmer et al. *Vaccine*, vol. 30, no. 30, pp. 4414–4418, 2012.
20. The role of viral nucleic acid recognition in dendritic cells for innate and adaptive antiviral immunity. Eisenacher et al. *Immunobiology*, vol. 212, no. 9-10, pp. 701–714, 2008.
21. Processing and presentation of HLA class I and II epitopes by dendritic cells after transfection with in vitro-transcribed MUC1 RNA. Dorfel et al, *Blood*, vol. 105, no. 8, pp. 3199–3205, 2005.
22. Cotransfection of dendritic cells with RNA coding for HER-2/neu and 4-1BBL increases the induction of tumor antigen specific cytotoxic T lymphocytes. Grunebach et al. *Cancer Gene Therapy*, vol. 12, no. 9, pp. 749–756, 2005.
23. α -Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. Meng et al. *Cancer Res* 2001;61:8782-6.
24. Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients. Butterfield et al. *J Transl Med* 2014;12:86
25. A comparison of gene transfer methods in human dendritic cells. Arthur et al. *Cancer Gene Ther* 1997;4:17-25.
26. Gene-modified dendritic cells for use in tumor vaccines. Kirk et al. *Hum. Gene Ther* 2000;11:797-806
27. Cancer vaccines. Butterfield. *BMJ* 2015;350:h988
28. Oncolytic viruses: a new class of immunotherapy drugs. Kaufman et al. *Nature Reviews Drug Discovery* 14, 642–662 (2015)
29. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. Andtbacka et al. *J. Clin. Oncol. Journal of Clinical Oncology* 33, no. 25:2780-2788 (2015). **Phase III clinical trial that led to the pending FDA approval of T-VEC for clinical use in the United States for melanoma.**
30. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. Small et al. *J Clin Oncol* 2006; 24:3089-3094.
31. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. Kantoff et al. *N Engl J Med* 2010; 363:411-422
32. Integrated Data From 2 Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trials of Active Cellular Immunotherapy With Sipuleucel-T in Advanced Prostate Cancer. Higano et al. *Cancer* 2009;115:3670–9
33. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Beer et al. *Clin Cancer Res.* 2011 Jul 1;17(13):4558-67
34. Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. Bystryn et al. *Clin Cancer Res.* 2001 Jul;7(7):1882-7.
35. Available at: <http://www.polynoma.com/prior-clinical-trials/phase-2-studies>. Accessed December 2016.

36. Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer. Kantoff et al. *J Clin Oncol*. 2010 Mar 1;28(7):1099-105
37. PROSTVAC® targeted immunotherapy candidate for prostate cancer, Shore. *Immunotherapy* (2014) 6(3), 235–247
38. Immunologic and Prognostic Factors Associated with Overall Survival Employing a Poxviral-based PSA Vaccine in Metastatic Castrate-resistant Prostate Cancer. Gulley et al. *Cancer Immunol Immunother*. 2010 May ; 59(5): 663–674
39. Available at: <http://www.bavarian-nordic.com/pipeline/clinical-trials.asp>. Accessed November 2016.
40. Available at: <http://www.advantagene.com/Technology>. Accessed November 2016.
41. Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. Podrazil et al. *Oncotarget*. 2015 Jul 20;6(20):18192-205.
42. Available at: <http://www.nwbio.com/dcvax-l>. Accessed November 2016.
43. Dendritic cell immunotherapy for solid tumors: evaluation of the DCVax® platform in the treatment of glioblastoma multiforme. Hdeib and Sloan. *CNS Oncol*. (2015) 4(2), 63–69.
44. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Phuphanich et al. *Cancer Immunol Immunother* (2013) 62:125–135
45. A randomized, double-blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients. Wen et al. *Neuro-Oncology* 16:v8– v22, 2014
46. Available at: <http://www.gradalisinc.com/index.php/clinical-trials.html>. Accessed November 2016.
47. TGF-β1 prevents the noncognate maturation of human dendritic Langerhans cells. Geissmann et al. *Journal of Immunology* Volume 162, Issue 8, 15 April 1999, Pages 4567-4575
48. Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer. Oh et al. *Gynecol Oncol*. 2016 Dec;143(3):504-510.
49. Available at: <http://www.immunovative.com/>. Accessed November 2016.
50. The anti-tumor effect of allogeneic bone marrow/ stem cell transplant without graft vs. host disease toxicity and without a matched donor requirement? Har-Noy and Slavin. *Medical Hypotheses* (2008) 70, 1186–1192
51. Response of HER2+ breast cancer patients to allogeneic cell immunotherapy. Har-Noy et al. *J Clin Oncol* 30, 2012 (suppl; abstr e13013)
52. Lung Cancer – Vaccines. Kelly and Giaccone. *Cancer J*. 2011 September ; 17(5): 302–308
53. Induction of Immune Responses and Clinical Efficacy in a Phase II Trial of IDM-2101, a 10-Epitope Cytotoxic T-Lymphocyte Vaccine, in Metastatic Non–Small-Cell Lung Cancer. Barve et al. *J Clin Oncol*. 2008 Sep 20;26(27):4418-25.
54. Anti-idiotypic antibodies as cancer vaccines: achievements and future improvements. Ladjemi. *Front Oncol*. 2012 Nov 6;2:158.
55. Racotumomab - a novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer. Gajdosik. *Drugs Today (Barc)*. 2014 Apr;50(4):301-7
56. Active specific immunotherapy with racotumomab in the treatment of advanced non small cell lung cancer (NSCLC). Macias et al. *Eur Soc Med Oncol (ESMO) sci Edu Conf* 2012. Abst 1238PD
57. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. Travis et al. *J Clin Oncol* 2013;31:992-1001
58. Pathway Targeted Immunotherapy: Rationale and Evidence of Durable Clinical Responses with a Novel, EGF-directed Agent for Advanced NSCLC. Rosell et al. *J Thorac Oncol*. 2016 Nov;11(11):1954-1961
59. Immunotherapy in lung cancer. Villaruz et al. *Transl Lung Cancer Res* 2014;3(1):2-14
60. Potential chemosensitization effect of tergenpumatulcel-L immunotherapy in treated patients with advanced non-small cell lung cancer (NSCLC). Morris et al. *J Clin Oncol* 2013;31:abstr 8094. Available at: <http://meetinglibrary.asco.org/content/83490?format=posterimg&poster=1>. Accessed November 2016.

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client's acceptance of the Service according the description proposed by the Company.
3. **Cancellation policy.** The Company's cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client's cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 813155
E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and "the spiral logo" are UK Registered Trademarks, 2009